Market Overview

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade

Biogen Inc (NASDAQ: BIIB) shares gained more than 25% earlier this year when the company said it planned a regulatory filing for its Alzheimer's drug aducanumab following a new data analysis. 

Ahead of the Dec. 5 presentation of aducanumab data at the Clinical Trials on Alzheimer's Disease annual congress, Baird put forward a bearish thesis on why the pipeline asset is unlikely to receive FDA approval. 

The Analyst

Brian Skorney downgraded Biogen from Neutral to Underperform with a $250 price target.

The Thesis

Biogen's CTAD presentation could serve as a meaningful negative catalyst for Biogen, with the hype around aducanumab descending into broader critique of the full data set and the company's decision to file based on it, Skorney said in a Monday note. (See his track record here.)

When the clinical benefit as measured from the EMERGE study is characterized, it is going to disappoint, the analyst said.

The numerical benefit is around 0.4 points compared to 0.5 points for Eisai Co., Ltd's (OTC: ESALY) marketed drug Aricept and 0.34 points for Eli Lilly And Co's (NYSE: LLY) pipeline asset solaneuzumab.

The safety disclosure for aducanumab is at the bare minimum, he said. 

Aducanumab falls far short of a compelling argument for approval, Skorney said. 

"The bottom line is, the FDA standard of approval is substantial evidence of efficacy and the cumulative data for aducanumab falls really far short of this standard to anyone but the most ardent GOOP subscribers." 

Price Action

Biogen shares were down 2.58% at $292.06 at the time of publication Monday. 

Related Links:

Benzinga's Top Upgrades, Downgrades For December 2, 2019

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Latest Ratings for BIIB

Jul 2020Morgan StanleyUpgradesUnderweightOverweight
Jul 2020Morgan StanleyMaintainsUnderweight
Jun 2020RBC CapitalMaintainsSector Perform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Aducanumab BairdAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

UBERRBC CapitalMaintains50.0
WIXJMP SecuritiesMaintains363.0
CVIJP MorganInitiates Coverage On22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at